| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
IC50: 23.6 nM (EGFRLR/TM/CS) and 307.5 nM EGFRWT)[1]
EGFR (wild-type and mutant forms). EGFR-IN-70 is an EGFR inhibitor with IC50 values of 23.6 nM for the EGFRLR/TM/CS mutant and 307.5 nM for wild-type EGFR (EGFRWT). |
|---|---|
| ln Vitro |
With IC50 values of 0.052, 0.644, and 2.003 μM, respectively, EGFR-IN-70 (compound 18j) (72 hours) has anti-proliferative activity and inhibits the proliferation of Ba/F3-EGFR19del/TM/CS, PC-9-OR-EGFR19del/TM/CS, and A431-EGFRWT cells[1]. The phosphorylation of EGFR can be suppressed by EGFR-IN-70 (compound 18j) (0-1000 nM; 2 hours; Ba/F3-EGFR19del/TM/CS and PC-9-OR-EGFR19del/TM/CS cells)[1].
EGFR-IN-70 inhibits EGFRLR/TM/CS with an IC50 of 23.6 nM and EGFRWT with an IC50 of 307.5 nM, demonstrating selectivity for this mutant over the wild-type receptor. It has anti-proliferation activity and inhibits the phosphorylation of EGFR in cancer cells. |
| ln Vivo |
EGFR-IN-70 is an in vitro research tool used to study cancer. It has demonstrated anti-proliferative activity and inhibits EGFR phosphorylation in cancer cells. Its selectivity for the mutant over wild-type EGFR suggests it may be a useful tool for overcoming drug resistance in specific patient populations.
|
| Enzyme Assay |
Cell-free EGFR kinase assays are performed using recombinant human wild-type EGFR (EGFRWT) and the EGFRLR/TM/CS mutant. The compound is incubated with the enzyme and a peptide substrate in the presence of ATP for 30-60 minutes. Kinase activity is measured using a luminescence-based ADP detection kit. IC50 values of 23.6 nM (mutant) and 307.5 nM (WT) are calculated.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Ba/F3-EGFR19del/TM/CS and PC-9-OR-EGFR19del/TM/CS cells Tested Concentrations: 1 , 3, 10, 30, 100, 300 and 1000 nM Incubation Duration: 2 hrs (hours) Experimental Results: Suppressed phosphorylation of the EGFR and the downstream signaling ERK level. EGFR-mutant cancer cell lines (e.g., those harboring the EGFRLR/TM/CS mutation) are seeded in 96-well plates and treated with increasing concentrations of EGFR-IN-70 for 72 hours. Cell viability is assessed by the MTT or CellTiter-Glo assay. The inhibition of EGFR phosphorylation (p-EGFR) and downstream signaling (p-ERK, p-AKT) is measured by Western blot. |
| Animal Protocol |
No specific in vivo animal protocols are published. For potential in vivo studies, EGFR-IN-70 would be administered to mice bearing xenografts of EGFRLR/TM/CS mutant-driven tumors. Dosing regimens are not specified. Tumor growth would be monitored, and at study termination, tumors would be excised for pharmacodynamic analysis.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data are reported for EGFR-IN-70. The molecular weight is 626.17 (C31H36ClN5O5S). It is soluble in DMSO (100 mg/mL). For in vivo studies, it would be formulated in a vehicle such as 0.5% methylcellulose. Its half-life, oral bioavailability, and clearance have not been characterized. It is stored at -20degC.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for EGFR-IN-70. As an EGFR inhibitor, on-target toxicity may include skin rash and gastrointestinal effects. Its selectivity for the mutant over wild-type EGFR may confer a wider therapeutic window. The compound is a research chemical and is not intended for human use.
|
| References | |
| Additional Infomation |
Other information: EGFR-IN-70 (CAS 2926716-96-1) is a research compound, not FDA-approved. It is a potent EGFR inhibitor with an IC50 of 23.6 nM for the EGFRLR/TM/CS mutant. It is a valuable tool for studying resistance mechanisms in NSCLC. Purity >98%. For research use only.
|
| Exact Mass |
625.213
|
|---|---|
| CAS # |
2926716-96-1
|
| PubChem CID |
164887498
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
43
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCS(=O)(=O)N1C=C2C3=C1C=C(C=C3)OCCCCCCOC4=C(C=C(C(=C4)NC5=NC=C(C2=N5)Cl)C)N6CCOCC6
|
| InChi Key |
SOZJLUNPQMFFFL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H36ClN5O5S/c1-3-43(38,39)37-20-24-23-9-8-22(17-27(23)37)41-12-6-4-5-7-13-42-29-18-26(34-31-33-19-25(32)30(24)35-31)21(2)16-28(29)36-10-14-40-15-11-36/h8-9,16-20H,3-7,10-15H2,1-2H3,(H,33,34,35)
|
| Chemical Name |
27-chloro-4-ethylsulfonyl-21-methyl-19-morpholin-4-yl-10,17-dioxa-4,23,25,28-tetrazapentacyclo[22.3.1.15,9.118,22.02,6]triaconta-1(28),2,5,7,9(30),18,20,22(29),24,26-decaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (159.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
